SGLT2 inhibitors were not clearly linked with myocarditis in patients receiving immune checkpoint inhibitors, after propensity score matching (RR 1.001, 95% CI 0.417-2.401).
“The risk of AMI (RR 0.85, 95% CI: 0.592-1.212, p-value 0.3625) and myocarditis (RR 1.001, 95% CI: 0.417-2.401, p-value 0.998) was similar between both groups.”
CHIP-associated somatic mutations are associated with myocarditis in humans (advanced heart failure undergoing heart transplantation; prior myocarditis) (3/5 vs 4/99; odds ratio 32.2, p=0.0018).
“CHIP mutations were enriched in patients with prior myocarditis (3/5 vs 4/99; Fisher’s exact test odds ratio 32.2, p=0.0018)”
Immune checkpoint inhibitors are linked with a higher risk of myocarditis in humans (cancer patients under ICI therapy (2021-2023 vs 2018-2020)) (OR 2.64, 95% CI 1.10-6.36, P = 0.03).
“Patients enrolled between 2021 and 2023 showed higher incidence of myocarditis (odds ratio [OR]: 2.64; 95% confidence interval [CI]: 1.10-6.36; P = 0.03)”
Humanscancer patients under ICI therapy (2021-2023 vs 2018-2020)
Myocarditis is associated with sudden cardiac death in humans (amateur athletes with recent respiratory infections).
“followed by atherosclerotic coronary artery disease-particularly in athletes older than 35 years-and myocarditis, mainly in younger individuals with recent respiratory infections.”
Reviewamateur athletes with recent respiratory infections
Heart muscle disease or serious rhythm problems occurred in 11% of people with early warning conditions, compared with 1.8% of controls.Heart muscle disease or serious rhythm problems occurred in 11% of people with early warning conditions, compared with 1.8% of controls.
Among 70,982 adults followed for up to five years, researchers identified 65 lower-risk and 53 higher-risk associations compared with other diabetes drugs.Among 70,982 adults followed for up to five years, researchers identified 65 lower-risk and 53 higher-risk associations compared with other diabetes drugs.